news M
ediderma has developed the next-generation, Ferulac Peel System, which combines a chemical peel composed of ferulic acid,
phloretin, fruit acids, and retinol, with liposomal active ingredients capable of stimulating the creation of p53 protein. The p53 protein has the ability to prevent damage from sun exposure and exerts an antioxidant and chemopreventive effect, which reduces the incidence of skin cancer. Harnessing nanotechnology, Mediderma has managed to encapsulate nanoadditive ingredients in lipid bubbles able to penetrate the skin layers. Thus, treatments are much more effective and safer. All these ingredients have a specific purpose Ferulic acid repairs DNA damage, reduces hyperpigmentation and is an antioxidant
Phloretin reduces collagen and elastin degradation
Fruit acids carry out exfoliation, improve penetration of other active ingredients and enhance combined action of ferulic acid and phloretin
NuMedii, Inc. have announced the formation of a research alliance with Allergan to explore new therapeutic options for the potential treatment of psoriasis. The companies will use NuMedii’s predictive Big Data intelligence platform technology, which enables the discovery of new uses for medicines across a number of therapeutic areas. NuMedii has already generated multiple lead compounds/candidates by using its
| NEWS
A round-up of news stories in the aesthetic and anti-ageing medicine industry
MEDIDERMA DEVELOPS NEW FERULAC PEEL SYSTEM TO REPAIR DNA DAMAGE
NANOTECHNOLOGY SYSTEM WITH ANTIOXIDANT AND SUNSCREEN PROPERTIES
summer when there is usually greater sun exposure. Mediderma, Valencian company
Retinol combats cellular aging and acne. The Ferulac Peel System can be used at any time of year for any age group. It can also be used in all skin types, even on seborrheic skin or the most sensitive parts of the body, and around the eyes and neck, without risk of spots, itching or burning. This system reinforces the skin’s protective
barrier, acting against internal aggressions such as stress and fatigue; or external, such as pollution, smoke, and especially against the harmful effects of solar radiation. It is an excellent treatment to prepare the skin for
founded 25 years ago by dermatologist Dr. Gabriel Serrano, carried out pioneer work in Spain that resulted in the introduction of a complete line of chemical peels. It specializes in the manufacture and marketing of dermo- cosmetic products created by health professionals for dermatologists and aesthetic physicians. Mediderma began the development of classic peel lines that include lactic acid (Lactipeel), mandelic acid (Mandelac), azelaic acid (Azelac Peel), salicylic acid (Salipeel) and retinol (Retises CT Yellow Peel). Mediderma has developed an important
R&D line based on dermatological studies and participates in joint studies with masters in Aesthetic Medicine of ten Spanish universities. Mediderma collaborates with the Spanish Society of Aesthetic Medicine (SEME), the Spanish Society of Medicine and Aesthetic Surgery (SEMCC) and the Spanish Association of Dermatology and Venereology (AEDV).
NUMEDII, INC. AND ALLERGAN LAUNCH RESEARCH ALLIANCE
data intelligence technology for psoriasis, which will be the focus of the research alliance with Allergan. Under the terms of the
agreement governing the research alliance, NuMedii will provide Allergan with proprietary, de-risked therapeutic candidates for psoriasis that are compatible with the 505b2 drug development regulatory pathway. NuMedii and Allergan may select and evaluate lead candidates in proof-of-concept disease models
for potential further development. ‘We are excited to partner with
Allergan to explore innovative treatments for the potential treatment of psoriasis,’ stated Gini Deshpande, Ph.D., chief executive officer, NuMedii, Inc. ‘As a world- class company in the field of medical dermatology, Allergan is an ideal research partner for NuMedii’s psoriasis program.’ NuMedii’s proprietary and dynamic Big Data technology
consists of hundreds of millions of human, biological, pharmacological and clinical data points that NuMedii has normalized and annotated. NuMedii integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases. NuMedii is initially using its Big Data technology to discover and de-risk new indications for safe, existing drugs.
prime-journal.com | October 2015 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72